Effect of inclisiran on lipids in primary prevention: the ORION-11 trial.

Kausik K RayDavid KallendLawrence A LeiterFrederick J RaalWolfgang KoenigMark J JarosGregory G SchwartzUlf LandmesserLorena Garcia CondeR Scott Wrightnull null

Published in: European heart journal (2022)

Inclisiran was generally well-tolerated in primary prevention patients with elevated LDL-C, who derived significant reductions in atherogenic lipoprotein levels with twice-yearly maintenance dosing.

Keyphrases

low density lipoprotein
study protocol
phase iii
clinical trial
phase ii
fatty acid
randomized controlled trial